Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017.

Hampel B, Kusejko K, Kouyos RD, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmidt AJ, Nguyen H, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Braun DL, Fehr J; Swiss HIV Cohort Study group.

HIV Med. 2019 Dec 18. doi: 10.1111/hiv.12821. [Epub ahead of print]

PMID:
31849182
2.

Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.

Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A.

Open Forum Infect Dis. 2019 Dec 8;6(12):ofz500. doi: 10.1093/ofid/ofz500. eCollection 2019 Dec.

3.

Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction.

Combes JD, Clifford GM, Günthard HF, Hauser C, Darling KEA, Valladares P, Battegay M, Waldeck F, Bernasconi E, Bertisch B, Hirsch HH, Brenner N, Waterboer T, Scherrer AU; Swiss HIV Cohort Study.

Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784. [Epub ahead of print]

PMID:
31722114
4.

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients.

Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagiola D, Schmid P, Günthard HF, Bernasconi E, Boeni J, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Calmy A.

Open Forum Infect Dis. 2019 Jul 12;6(10):ofz330. doi: 10.1093/ofid/ofz330. eCollection 2019 Oct. Erratum in: Open Forum Infect Dis. 2019 Dec 08;6(12):ofz500.

5.

2019 update of the drug resistance mutations in HIV-1.

Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW, Richman DD.

Top Antivir Med. 2019 Sep;27(3):111-121.

6.

Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals.

Lodi S, Günthard HF, Gill J, Phillips AN, Dunn D, Vu Q, Siemieniuk R, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Reiss P, van Sighem A, Boender TS, Porter K, Gilson R, Paraskevis D, Simeon M, Vourli G, Moreno S, Jarrin I, Sabin C, Hernán MA.

J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):314-320. doi: 10.1097/QAI.0000000000002135.

PMID:
31609929
7.

Self-reported neurocognitive impairment in people living with HIV: Characterizing clusters of patients with similar changes in self-reported neurocognitive impairment 2013-2017 in the Swiss HIV Cohort Study.

Kusejko K, Salazar-Vizcaya L, Braun DL, Tarr PE, Bernasconi E, Doco-Lecompte T, Cavassini M, Schmid P, Du Pasquier R, Hauser C, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Sep 3. pii: ciz868. doi: 10.1093/cid/ciz868. [Epub ahead of print]

PMID:
31504323
8.

Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases.

Kufner V, Plate A, Schmutz S, Braun DL, Günthard HF, Capaul R, Zbinden A, Mueller NJ, Trkola A, Huber M.

Genes (Basel). 2019 Aug 29;10(9). pii: E661. doi: 10.3390/genes10090661.

9.

Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017.

Ruffieux Y, Lemsalu L, Aebi-Popp K, Calmy A, Cavassini M, Fux CA, Günthard HF, Marzolini C, Scherrer A, Vernazza P, Keiser O, Egger M; Swiss HIV Cohort Study and the Swiss National Cohort.

J Int AIDS Soc. 2019 Aug;22(8):e25339. doi: 10.1002/jia2.25339.

10.

Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.

Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Kok YL, Thorball CW, Borghesi A, Parbhoo S, Wieser M, Böni J, Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M, Kouyos RD, Günthard HF, Metzner KJ; Swiss HIV Cohort Study.

Nat Commun. 2019 Jul 19;10(1):3193. doi: 10.1038/s41467-019-10884-9.

11.

IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.

Wójtowicz A, Bibert S, Taffé P, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Osthoff M, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2019 Sep 1;33(11):1719-1727. doi: 10.1097/QAD.0000000000002283.

12.

Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells.

Liechti T, Kadelka C, Braun DL, Kuster H, Böni J, Robbiani M, Günthard HF, Trkola A.

J Exp Med. 2019 Sep 2;216(9):2071-2090. doi: 10.1084/jem.20181124. Epub 2019 Jun 20.

PMID:
31221742
13.

Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.

Barcelo C, Aouri M, Courlet P, Guidi M, Braun DL, Günthard HF, Piso RJ, Cavassini M, Buclin T, Decosterd LA, Csajka C; Swiss HIV Cohort Study .

J Antimicrob Chemother. 2019 Sep 1;74(9):2690-2697. doi: 10.1093/jac/dkz217.

PMID:
31119275
14.

HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected.

Nguyen H, Thorball CW, Fellay J, Böni J, Yerly S, Perreau M, Klimkait T, Kusejko K, Bachmann N, Chaudron SE, Paioni P, Thurnheer MC, Battegay M, Cavassini M, Vernazza P, Bernasconi E, Günthard HF, Kouyos R; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):508-515. doi: 10.1097/QAI.0000000000002077.

PMID:
31107301
15.

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2019;24(5):343-353. doi: 10.3851/IMP3310.

PMID:
30985290
16.

Clusters of Sexual Behavior in Human Immunodeficiency Virus-positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends.

Salazar-Vizcaya L, Kusejko K, Schmidt AJ, Carrillo-Montoya G, Nicca D, Wandeler G, Braun DL, Fehr J, Darling KEA, Bernasconi E, Schmid P, Günthard HF, Kouyos RD, Rauch A.

Clin Infect Dis. 2020 Jan 16;70(3):416-424. doi: 10.1093/cid/ciz208.

17.

Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study .

Clin Infect Dis. 2020 Jan 2;70(2):297-303. doi: 10.1093/cid/ciz178.

PMID:
30843028
18.

A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases.

Kusejko K, Bachmann N, Chaudron SE, Nguyen H, Braun DL, Hampel B, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

J Infect Dis. 2019 Jun 19;220(2):244-253. doi: 10.1093/infdis/jiz093.

PMID:
30835292
19.

Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.

Carlisle LA, Turk T, Kusejko K, Metzner KJ, Leemann C, Schenkel CD, Bachmann N, Posada S, Beerenwinkel N, Böni J, Yerly S, Klimkait T, Perreau M, Braun DL, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

J Infect Dis. 2019 Jun 19;220(2):254-265. doi: 10.1093/infdis/jiz094.

PMID:
30835266
20.

Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era.

Salazar-Vizcaya L, Kouyos RD, Metzner KJ, Caraballo Cortes K, Böni J, Shah C, Fehr J, Braun DL, Bernasconi E, Mbunkah HA, Hoffmann M, Labhardt N, Cavassini M, Rougemont M, Günthard HF, Keiser O, Rauch A; Swiss HIV Cohort Study.

J Infect Dis. 2019 Jun 5;220(1):91-99. doi: 10.1093/infdis/jiz069.

21.

Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial.

Braun DL, Turk T, Tschumi F, Grube C, Hampel B, Depmeier C, Schreiber PW, Brugger SD, Greiner M, Steffens D, De Torrenté-Bayard C, Courlet P, Neumann K, Kuster H, Flepp M, Bertisch B, Decosterd L, Böni J, Metzner KJ, Kouyos RD, Günthard HF.

Clin Infect Dis. 2019 Oct 15;69(9):1489-1497. doi: 10.1093/cid/ciy1131.

PMID:
30601950
22.

Can Directionality of HIV Transmission be Predicted by Next-Generation Sequencing Data?

Günthard HF, Kouyos R.

J Infect Dis. 2019 Sep 26;220(9):1393-1395. doi: 10.1093/infdis/jiy737. No abstract available.

PMID:
30590738
23.

Reply to Ambrosioni et al.

Günthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, Jacobsen DM, Richman DD.

Clin Infect Dis. 2019 May 17;68(11):1977-1978. doi: 10.1093/cid/ciy1022. No abstract available.

PMID:
30520997
24.

Baseline Genotype Testing to Assess Drug Resistance Before Beginning HIV Treatment-Reply.

Saag MS, Günthard HF, Smith DM.

JAMA. 2018 Nov 27;320(20):2154. doi: 10.1001/jama.2018.15946. No abstract available.

25.

Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.

Bachmann N, von Braun A, Labhardt ND, Kadelka C, Günthard HF, Sekaggya-Wiltshire C, Castelnuovo B, Kambugu A, Lejone TI, Böni J, Yerly S, Perreau M, Klimkait T, Kouyos RD, Fehr J; Swiss HIV Cohort Study.

J Antimicrob Chemother. 2019 Feb 1;74(2):468-472. doi: 10.1093/jac/dky436.

PMID:
30476115
26.

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.

Kusejko K, Kadelka C, Marzel A, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Virus Evol. 2018 Sep 18;4(2):vey024. doi: 10.1093/ve/vey024. eCollection 2018 Jul. Review.

27.

Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma.

Bibert S, Wójtowicz A, Taffé P, Tarr PE, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Kaiser L, Osthoff M, Fellay J, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2018 Nov 28;32(18):2759-2765. doi: 10.1097/QAD.0000000000002004.

28.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Kouyos RD, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun DL, Scherrer AU, Weber J, Uhr T, Baumann NS, Leemann C, Kuster H, Chave JP, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner KJ, Günthard HF, Trkola A; Swiss HIV Cohort Study.

Nature. 2018 Sep;561(7723):406-410. doi: 10.1038/s41586-018-0517-0. Epub 2018 Sep 10.

PMID:
30202088
29.

High Number of Potential Transmitters Revealed in a Population-based Systematic Hepatitis C Virus RNA Screening Among Human Immunodeficiency Virus-infected Men Who Have Sex With Men.

Braun DL, Hampel B, Martin E, Kouyos R, Kusejko K, Grube C, Flepp M, Stöckle M, Conen A, Béguelin C, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Böni J, Fehr JS; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Feb 1;68(4):561-568. doi: 10.1093/cid/ciy545.

PMID:
30107494
30.

High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.

Braun DL, Hampel B, Kouyos R, Nguyen H, Shah C, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmid P, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Böni J, Fehr JS; Swiss HIV Cohort Study.

Clin Infect Dis. 2019 Feb 1;68(4):569-576. doi: 10.1093/cid/ciy547.

PMID:
30107485
31.

Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, Jacobsen DM, Richman DD.

Clin Infect Dis. 2019 Jan 7;68(2):177-187. doi: 10.1093/cid/ciy463.

32.

Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.

Kusejko K, Marzel A, Hampel B, Bachmann N, Nguyen H, Fehr J, Braun DL, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD; Swiss HIV Cohort Study.

HIV Med. 2018 Nov;19(10):688-697. doi: 10.1111/hiv.12660. Epub 2018 Jul 26.

PMID:
30051600
33.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA.

JAMA. 2018 Jul 24;320(4):379-396. doi: 10.1001/jama.2018.8431.

34.

Spontaneous reactivation of latent HIV-1 promoters is linked to the cell cycle as revealed by a genetic-insulators-containing dual-fluorescence HIV-1-based vector.

Kok YL, Schmutz S, Inderbitzin A, Neumann K, Kelley A, Jörimann L, Shilaih M, Vongrad V, Kouyos RD, Günthard HF, Berens C, Metzner KJ.

Sci Rep. 2018 Jul 5;8(1):10204. doi: 10.1038/s41598-018-28161-y.

35.

[Infections during Immunosuppression].

Depmeier C, Günthard HF, Steiner UC.

Praxis (Bern 1994). 2018 Jun;107(13):689-698. doi: 10.1024/1661-8157/a003003. Review. German.

PMID:
29921180
36.

Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver.

Wymant C, Blanquart F, Golubchik T, Gall A, Bakker M, Bezemer D, Croucher NJ, Hall M, Hillebregt M, Ong SH, Ratmann O, Albert J, Bannert N, Fellay J, Fransen K, Gourlay A, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos R, Laeyendecker O, Liitsola K, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Cornelissen M, Kellam P, Reiss P, Fraser C; BEEHIVE Collaboration.

Virus Evol. 2018 May 18;4(1):vey007. doi: 10.1093/ve/vey007. eCollection 2018 Jan.

37.

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis.

Marzel A, Kusejko K, Weber R, Bruggmann P, Rauch A, Roth JA, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study .

Open Forum Infect Dis. 2018 May 19;5(5):ofy078. doi: 10.1093/ofid/ofy078. eCollection 2018 May.

38.

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.

Kadelka C, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun DL, Huber M, Scherrer AU, Weber J, Uhr T, Kuster H, Misselwitz B, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos RD, Günthard HF, Trkola A; Swiss HIV Cohort Study.

J Exp Med. 2018 Jun 4;215(6):1589-1608. doi: 10.1084/jem.20180246. Epub 2018 May 24.

39.

OMIP-047: High-Dimensional phenotypic characterization of B cells.

Liechti T, Günthard HF, Trkola A.

Cytometry A. 2018 Jun;93(6):592-596. doi: 10.1002/cyto.a.23488. Epub 2018 May 21. Review. No abstract available.

40.

HIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient Clinic.

von Braun A, Sekaggya-Wiltshire C, Bachmann N, Ssemwanga D, Scherrer AU, Nanyonjo M, Kapaata A, Kaleebu P, Günthard HF, Castelnuovo B, Fehr J, Kambugu A.

J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):566-573. doi: 10.1097/QAI.0000000000001717.

41.

CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells.

Kurioka A, Cosgrove C, Simoni Y, van Wilgenburg B, Geremia A, Björkander S, Sverremark-Ekström E, Thurnheer C, Günthard HF, Khanna N; Swiss HIV Cohort Study; Oxford IBD Cohort Investigators, Walker LJ, Arancibia-Cárcamo CV, Newell EW, Willberg CB, Klenerman P.

Front Immunol. 2018 Apr 9;9:486. doi: 10.3389/fimmu.2018.00486. eCollection 2018.

42.

MRI and PET-CT Failed to Differentiate Between Hepatic Malignancy and Brucelloma.

Schreiber PW, Schmid A, Fagagnini S, Kröger A, Vrugt B, Reiner CS, Boggian K, Schiesser M, Müllhaupt B, Günthard HF.

Open Forum Infect Dis. 2018 Mar 8;5(4):ofy052. doi: 10.1093/ofid/ofy052. eCollection 2018 Apr.

43.

Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16.

Mbunkah HA, Marzel A, Schmutz S, Kok YL, Zagordi O, Shilaih M, Nsanwe NN, Mbu ET, Besong LM, Sama BA, Orock E, Kouyos RD, Günthard HF, Metzner KJ.

J Antimicrob Chemother. 2018 Jul 1;73(7):1917-1929. doi: 10.1093/jac/dky103.

PMID:
29635462
44.

No Effect of Pegylated Interferon-α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients.

Strouvelle VP, Braun DL, Vongrad V, Scherrer AU, Kok YL, Kouyos RD, Stöckle M, Rauch A, Darling K, Hoffmann M, Metzner KJ, Günthard HF; Zurich Primary HIV Infection Study and the Swiss HIV Cohort Study.

J Infect Dis. 2018 May 25;217(12):1883-1888. doi: 10.1093/infdis/jiy131.

PMID:
29528417
45.

Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics.

Kühnert D, Kouyos R, Shirreff G, Pečerska J, Scherrer AU, Böni J, Yerly S, Klimkait T, Aubert V, Günthard HF, Stadler T, Bonhoeffer S; Swiss HIV Cohort Study.

PLoS Pathog. 2018 Feb 20;14(2):e1006895. doi: 10.1371/journal.ppat.1006895. eCollection 2018 Feb.

46.

Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples.

Liechti T, Kadelka C, Ebner H, Friedrich N, Kouyos RD, Günthard HF, Trkola A.

J Immunol Methods. 2018 Mar;454:48-58. doi: 10.1016/j.jim.2017.12.003. Epub 2017 Dec 22.

47.

Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.

Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

AIDS. 2018 Jan 28;32(3):327-335. doi: 10.1097/QAD.0000000000001692.

48.

Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.

Bertels F, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard HF, Böni J, Yerly S, Klimkait T, Aubert V, Battegay M, Rauch A, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer AU, Müller V, Bonhoeffer S, Kouyos R, Regoes RR; Swiss HIV Cohort Study.

Mol Biol Evol. 2018 Jan 1;35(1):27-37. doi: 10.1093/molbev/msx246.

49.

High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection.

Braun DL, Marzel A, Steffens D, Schreiber PW, Grube C, Scherrer AU, Kouyos RD, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2018 Feb 10;66(5):735-742. doi: 10.1093/cid/cix873.

PMID:
29028966
50.

Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.

Turk T, Bachmann N, Kadelka C, Böni J, Yerly S, Aubert V, Klimkait T, Battegay M, Bernasconi E, Calmy A, Cavassini M, Furrer H, Hoffmann M, Günthard HF, Kouyos RD; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni P, Rauch A, Rudin C, Scherrer AU, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

Elife. 2017 Sep 12;6. pii: e28721. doi: 10.7554/eLife.28721.

Supplemental Content

Loading ...
Support Center